文献速递肾小球疾病

组学研究全面理解IgA肾病:现状与未来方向

Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本文综述了基因组学、转录组学、表观基因组学、蛋白质组学和代谢组学等多层次组学数据在识别IgA肾病分子亚型中的作用。通过整合组学数据,可发现特异性分子生物标志物,从而更精确地对患者进行分层,并促进靶向治疗决策和非侵入性生物标志物的开发。文章还提出了组学研究框架,并概述了障碍与潜在解决方案。

要点

  • 组学整合有助于识别IgA肾病的分子亚型,实现更精准的患者分层。
  • 尿液蛋白质组和代谢组特征可能成为非侵入性生物标志物,用于评估肾脏损伤和随访。
  • 表观遗传因素(如microRNA)对转录组模式的调控可加深对发病机制的理解。

核心结论

  • 组学研究通过整合多组学数据,有望推动IgA肾病的精准诊断和个体化治疗。

研究设计与样本

  • 综述,聚焦于组学在识别IgA肾病分子亚型中的作用,整合基因组学、转录组学、表观基因组学、蛋白质组学和代谢组学等多层次数据。

主要发现

  • 基因组学可绘制常见和罕见IgA肾病风险等位基因谱,有助于更精确分层患者。
  • 转录组模式及其受microRNA等表观遗传因素的调控分析,可增进对疾病发病机制的理解。
  • 尿液蛋白质组和代谢组特征的特异性及其功能相关性,可能促进非侵入性生物标志物的开发。

临床怎么用

  • 组学方法可为靶向治疗决策提供信息,并支持新的临床决策。

局限性

  • 文章概述了组学研究的障碍和潜在解决方案,但未具体列出局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin A nephropathy (IgAN) is the most common worldwide primary glomerulonephritis with a strong autoimmune component. The disease shows variability in both clinical phenotypes and endpoints and can be potentially subdivided into more homogeneous subtypes through the identification of specific molecular biomarkers. This review focuses on the role of omics in driving the identification of potential molecular subtypes of the disease through the integration of multilevel data from genomics, transcriptomics, epigenomics, proteomics and metabolomics. First, the identification of molecular biomarkers, including mapping of the full spectrum of common and rare IgAN risk alleles, could permit a more precise stratification of IgAN patients. Second, the analysis of transcriptomic patterns and their modulation by epigenetic factors like microRNAs has the potential to increase our understanding in the pathogenic mechanisms of the disease. Third, the specificity of urinary proteomic and metabolomic signatures and the understanding of their functional relevance may contribute to the development of new non-invasive biomarkers for a better molecular characterization of the renal damage and its follow-up. All these approaches can give information for targeted therapeutic decisions and will support novel clinical decision making. In conclusion, we offer a framework of omic studies and outline barriers and potential solutions that should be used for improving the diagnosis and treatment of the disease. The ongoing decade is exploiting novel high-throughput molecular technologies and computational analyses for improving the diagnosis (precision nephrology) and treatment (personalized therapy) of the IgAN subtypes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Schena FP, Serino G, Sallustio F, et al. Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions. Nephrol Dial Transplant. 2018. PMID: 29905852. doi:10.1093/ndt/gfy130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。